Paul Berg is a biostatistician with over 20 years of experience working with observational studies and clinical trials. He specializes in studies supporting pharmaceutical development. Paul has worked across a range of therapeutic areas including psychiatry, neurology, diabetes, cardio-vascular, and immunology. He has designed and analyzed many different types of studies across Phases I-IV of pharmaceutical development including first-in-human, clinical pharmacology, proof-of-concept, dose-response, confirmatory, biopharmaceutical, and commercialization.
Currently Paul is the Lead Statistician for Chorus, an autonomous drug development group within Lilly Research Labs at Eli Lilly and Company. He earned a BS in mathematics (honors program) at the University of Notre Dame and an MS in biometry and epidemiology at the Medical University of South Carolina.